Revelation Biosciences stock hits 52-week low at $0.28
Revelation Biosciences Inc. (REVB) stock has plummeted to a 52-week low, touching down at $0.28, with a market capitalization ...
Ionis stock rises on FDA, EMA nod for SMA drug dose increase
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the ...
Hosted on MSN18h
Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing
Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now ...
Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch
Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...
Replimune stock soars on FDA priority review for melanoma treatment
Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...
Atara extends losses after FDA clinical hold
Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo.
Nasdaq3d
Sanofi's Opella: FDA Lifts Clinical Hold On OTC Cialis Trial
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq7d
ImmunityBio Provides Update On FDA Submissions For 2025
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq10d
FDA Reduced Nicotine Proposal Could Benefit 13 Mln Smokers, Highlights 22nd Century's VLN Cigarettes
VLN cigarettes are the first and only combustible tobacco products authorized by the FDA under its Modified Risk ... do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s ...
Scilex FDA submission for ELYXYB acute pain treatment acknowledged
PALO ALTO, Calif. - Scilex Holding Company (NASDAQ:SCLX), a $77.5 million market cap company known for its focus on non-opioid pain management products, reported that the U.S. Food and Drug ...
Stifel raises Disc Medicine stock target to $94, maintains Buy
Stifel analysts increased their price target for Disc Medicine (NASDAQ:IRON) shares to $94.00, up from the previous $90.00. Currently trading at $57.07 with a market capitalization of $1.7 billion, ...